Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Infliximab

Brand: Remicade® Inflectra® Remsima®
NICE TA: 329
Indication: First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LMMG Recommendation
Disease category: Gastro-intestinal system
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Infliximab is also recommended as a possible treatment for children or young people aged 6–17 years with severe ulcerative colitis, if conventional therapy hasn’t worked or isn’t suitable. (When used by children’s services NHS England is the responsible commissioner)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red